Nabi Biopharmaceuticals will sell its Biologics unit to Biotest Pharmaceuticals Corp. for $185 million. The purchase includes the unit’s products, including Nabi-HB (Hepatitis B Immune Globulin (Human)), and other plasma business assets, as well as Nabi’s state-of-the-art plasma protein production plant, and nine FDA-certified plasma collection centers across the U.S. The acquisition will include certain of Nabi’s Corporate Shared Services group assets and the company’s B...